Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME) (Louvre 3)

Allergan

Status: Completed

Conditions: Diabetic Macular Edema

Treatments: Drug: dexamethasone intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT03003416

GMA-EAME-EYE-0440

Details and patient eligibility

About

This study will evaluate the efficacy of Ozurdex® as prescribed in clinical practice in France for the treatment of Diabetic Macular Edema (DME).

Enrollment: 115 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patient with Diabetic Macular Edema (DME) treated with Ozurdex® in clinical practice.

Exclusion criteria

-Patient not residing in metropolitan France.

Trial design

115 participants in 1 patient group

OZURDEX®

Description:

Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.

Treatment:

Drug: dexamethasone intravitreal implant